Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma

Haematologica

Volumn 88, Issue 9, 2003, Pages 1013-1021

  Mateo, Gema ^b   Corral, Mercedes ^b   Almeida, Julia ^b   López Berges, Consuelo ^b   Nieto, María Jesús ^b   García Marcos, Antonia ^b   Vázquez, Lourdes ^b   Del Cañizo, Consuelo ^b   Orfao, Alberto ^b   San Miguel, Jesús F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

Apheresis; Immunophenotyping; Multiple myeloma; Peripheral blood; Plasma cells

Indexed keywords

CYTOKINE; GROWTH FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MULTIPLE MYELOMA; PLASMA CELL; STEM CELL; TECHNIQUE;

ADULT; AGED; ANTIGENS, CD; BLOOD COMPONENT REMOVAL; BONE MARROW CELLS; FEMALE; GROWTH SUBSTANCES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; TISSUE AND ORGAN HARVESTING;

EID: 0141813571     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Française du Myelome. N Engl J Med 2001;11:91-7.
2. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995;13 Suppl 2:140-6.
3. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
4. Lokhorst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma: where do we stand? Br J Haematol 1999;106:18-27.
5. San Miguel JF, Blade J, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999;84:36-58.
6. Working Group of the UK Myeloma Forum. Guidelines: diagnosis and managements of multiple myeloma. Br J Haematol 2001;115:522-40.
7. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995;32:31-44.
8. Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997;11:111-31.
9. Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994;12:503-9.
10. Barlogie B, Jagannath S, Vesole D, Nancke S, Cheson B, Mattox S, et al. Superiority of autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.
11. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-93.
12. Henry JM, Sykes P, Brisco MJ, To LB, Juttner CA, Morley AA. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996;92:614-9.
13. Vescio R, Han EJ, Schiller G, Lee JC, Wu CH, Cao J, et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996;18:103-10.
14. Billadeau D, Prosper F, Verfaillie C, Weisdorf D, Van Ness BG. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia 1997;11:1565-70.
15. Cremer FW, Goldschmidt H, Moos M. Clonotypic B cells in the peripheral blood of patients with multiple myeloma. Blood 2001;97:2913-4.
16. Billadeau D, Van Ness BG, Kimlinger TK, Kyle RA, Therneau T, Greipp PR, et al. Clonal circulating cells are common in plasma cell disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and active myeloma. Blood 1996;88:289-96.
17. Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996;26:113-20.
18. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97:46-55.
19. + cells to remove circulating tumor cells. Blood 1996;87:1625-34.
20. Rawstron A, Barrans S, Blythe D, Davies F, English A, Pratt G, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999;104:138-43.
21. Omede P, Tarella C, Palumbo A, Argentino C, Caracciolo D, Corradini P, et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 1997;99:685-91.
22. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596-602.
23. Dreyfus F, Ribrag V, Leblond V, Ravaud P, Melle J, Quarre MC, et al. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995;15:707-11.
24. Lopez-Perez R, Garcia-Sanz R, Gonzalez D, Balanzategui A, Chillon MC, Alaejos I, et al. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000;14:1493-9.
25. Mitterer M, Oduncu F, Lanthaler AJ, Drexler E, Amaddii G, Fabris P, et al. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. Br J Haematol 1999;106:737-43.
26. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 1995;89:640-2.
27. Boccadoro M, Omede P, Dominietto A, Palumbo A, Bringhen S, Giaretta F, et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant 2000;25:25-9.
28. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997;19:337-42.
29. Pope B, Brown R, Gibson J, Joshua D. Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Bone Marrow Transplant 1997;20:205-10.
30. Ocqueteau M, Orfao A, Garcia R, San Miguel JF. Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection [letter; comment]. Br J Haematol 1996;93:251-2.
31. Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero D, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121-31.
32. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-100.
33. Almeida J, Orfao A, Mateo G, Ocqueteau M, Garcia-Sanz R, Moro MJ, et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol Paris 1999;4 7:119-27.
34. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-63.
35. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-12.
36. Occueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-65.
37. Schneider U, Lessen AV, Hunh D, Serke S. Two subsets of peripheral blood plasm cells defined by differential expression of CD45 antigen. Br J Haematol 1997;97:56-64.
38. San Miguel JF, Almeida J, Mateo G, Blade J, López-Berges MC, Caballero MD, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853-6.
39. Chronic Leukemia Myeloma Task Force. National Cancer Institute. Plasma Cell Myeloma. Proposed guidelines for protocol studies. Cancer Chemother Rep 1973;4:145-58.
40. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
41. Basso G, Buldini B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001;86:675-92.
42. Gazitt Y, Tian E, Barlogie B, Reading CL, Vesole DH, Jagannath S, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996;87:805-11.
43. Kiel K, Cremer FW, Ehrbrecht E, Wallmeier M, Hegenbart U, Goldschmidt H, et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 1998;21:1109-15.
44. Bird JM, Bloxham D, Samson D, Marcus RE, Russell NH, Kelsey SM, et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994;88:110-6.
45. Luque R. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients: diagnostic and clinical implications. Clin Exp Immunol 1998;112:410-8.
46. Vota AJ, Toh CH, Peel J, Greaves M. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994;86:180-2.
47. Mariette X, Fermand JP, Brouet JC. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994;14:47-50.
48. Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B et al. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998;28:501-8.
49. Linez LF, Crooks RL, Way SL, Granter N, Spencer A. Tumour kinetics in multiple myeloma before, during, and after treatment. Leuk Lymphoma 2001;40:373-84.
50. 3 integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002;87:836-45.